Royal Bank Of Canada Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Key Points

• Royal Bank of Canada raised its price target on Neurocrine to $180 (from $176) and keeps an "outperform" rating, implying about a 24% upside
• Recent operational momentum: Q1 revenue was about $805.5M (up ~28% YoY) with Ingrezza sales cited as a key driver and management reaffirming full‑year Ingrezza guidance, while EPS performance was mixed (reported $1.88); the company also announced an acquisition of Soleno to expand its pipeline.
• Market context: shares traded near $144.83 mid‑day, with a market cap of roughly $14.6B, a P/E of ~31, a 52‑week range of $115.66–$160.18, and high institutional ownership (~92.6%).

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) had its target price hoisted by equities researchers at Royal Bank Of Canada from $176.00 to $180.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an "outperform" rating on the stock. Royal Bank Of Canada's price target would suggest a potential upside of 24.29% from the company's current price.

NBIX has been the subject of a number of other research reports. Citigroup upped their price objective on shares of Neurocrine Biosciences from $204.00 to $242.00 and gave the company a "buy" rating in a report on Tuesday, April 7th. Weiss Ratings reissued a "hold (c+)" rating on shares of Neurocrine Biosciences in a report on Tuesday, April 21st. Zacks Research raised shares of Neurocrine Biosciences from a "strong sell" rating to a "hold" rating in a research note on Wednesday, April 15th. Leerink Partners increased their target price on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 22nd. Finally, Truist Financial lowered their target price on shares of Neurocrine Biosciences from $169.00 to $140.00 and set a "buy" rating for the company in a research note on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $182.50.

Neurocrine Biosciences Price Performance

Shares of NBIX traded up $9.77 during mid-day trading on Wednesday, reaching $144.83. The stock had a trading volume of 969,251 shares, compared to its average volume of 1,146,756. Neurocrine Biosciences has a 52-week low of $115.66 and a 52-week high of $160.18. The business's fifty day moving average is $130.37 and its 200 day moving average is $137.72. The firm has a market cap of $14.57 billion, a price-to-earnings ratio of 31.12, a P/E/G ratio of 0.67 and a beta of 0.34.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.36 by ($0.48). Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The firm had revenue of $805.50 million during the quarter, compared to analysts' expectations of $804.21 million. During the same period in the prior year, the company posted $1.69 EPS. The company's revenue for the quarter was up 28.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Neurocrine Biosciences will post 6.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. USA Financial Formulas acquired a new stake in shares of Neurocrine Biosciences during the fourth quarter worth about $25,000. Geneos Wealth Management Inc. lifted its position in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company's stock worth $25,000 after purchasing an additional 135 shares in the last quarter. Golden State Wealth Management LLC lifted its position in shares of Neurocrine Biosciences by 120.5% during the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company's stock worth $26,000 after purchasing an additional 100 shares in the last quarter. Eastern Bank acquired a new stake in shares of Neurocrine Biosciences during the third quarter worth about $27,000. Finally, DJE Kapital AG acquired a new stake in shares of Neurocrine Biosciences during the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 92.59% of the company's stock.

More Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Wedbush raised its price target on NBIX to $176 and kept an "outperform" rating, implying meaningful upside and likely supporting buy-side interest. Benzinga
• Positive Sentiment: Q1 results beat expectations: EPS and revenue topped consensus, net product sales rose ~44% YoY to roughly $811M, and management reaffirmed full-year INGREZZA sales guidance of $2.7–$2.8B — data that directly support valuation and near-term cash flow visibility. Q1 Press Release
• Positive Sentiment: INGREZZA sales were a key driver of the better-than-expected quarter, cited by multiple outlets — supporting the commercial growth story and analyst upgrades. Investing.com
• Positive Sentiment: Publication of expert recommendations for glucocorticoid dose reduction after initiating CRENESSITY (crinecerfont) — published in a peer-reviewed journal — should help clinicians reduce steroid burden in CAH patients and may accelerate real-world adoption. PR Newswire - CRENESSITY publication
• Positive Sentiment: Neurocrine announced a definitive agreement to acquire Soleno Therapeutics (including VYKAT XR for hyperphagia in Prader‑Willi), expanding the company's pipeline and near-term commercial opportunities; expected close in Q2 2026. Acquisition announcement
• Neutral Sentiment: Pipeline progress: initiation of a Phase 2 study of NBI-1117570 (M1/M4 agonist) in schizophrenia — a positive clinical update but earlier-stage and longer horizon for value realization. Seeking Alpha - presentation
• Neutral Sentiment: Analyst/market coverage and events: company to present at the Bank of America Health Care Conference (May 12) and several earnings call transcripts/analyst notes are circulating — useful for deeper due diligence but not immediate catalysts. Conference notice

About Neurocrine Biosciences

Neurocrine Biosciences NASDAQ: NBIX is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine's operations encompass drug discovery, clinical development and commercialization activities.

The company's lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.